PharmaMab is a Biotech Company created in 2010 which focus on the discovery and development of innovative drugs, mostly in the form on monoclonal antibodies for the treatment of cancer and other diseases with unmet medical need.
PharmaMab’ frontline candidates are two bispecific antibodies: the first against LGALS3BP (aka Mac-2 BP or Gal3-BP)/Endosialin (aka TEM1) and the second against LGALS3BP/ErbB-3 (aka HER-3). These products have shown significant therapeutic activity in a variety of preclinical models.

PharmaMab’s business strategy for the next 3 years is to develop these bispecifics from pre-clinical Phase to the achievement of clinical Phase I Proof-of-Concept and then to license out to Pharma/large Biotech companies, in exchange for upfront, success-based milestones and royalty fees.